Drug-induced parkinsonism

被引:77
作者
Lopez-Sendon, Jose [1 ]
Mena, Maria A. [2 ]
de Yebenes, Justo G. [1 ]
机构
[1] Hosp Ramon & Cajal, Serv Neurol, CIBERNED, E-28034 Madrid, Spain
[2] Hosp Ramon & Cajal, CIBERNED, E-28034 Madrid, Spain
关键词
antipsychotics; calcium channel blockers; dopamine receptor blocker; drug-induced; extrapyramidal side effects; neuroleptics; parkinsonism; CINNARIZINE-INDUCED PARKINSONISM; FLUNARIZINE-INDUCED PARKINSONISM; INDUCED EXTRAPYRAMIDAL REACTIONS; VESICULAR MONOAMINE TRANSPORTER; TARDIVE-DYSKINESIA; MOVEMENT-DISORDERS; ATYPICAL ANTIPSYCHOTICS; COGNITIVE IMPAIRMENT; ANTIDEPRESSANT DRUGS; PSYCHIATRIC-PATIENTS;
D O I
10.1517/14740338.2013.787065
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Drug-induced parkinsonism (DIP) is the second most common cause of parkinsonism after idiopathic Parkinson's disease (iPD). Initially reported as a complication of antipsychotics, it was later recognized as a common complication of antidepressants, calcium channel antagonists, gastrointestinal prokinetics, antiepileptic drugs and many other compounds. Despite being a major health problem in certain populations, it seems to be frequently overlooked by the medical community. Areas covered: This paper approaches the concept of DIP, reviews its epidemiology, clinical features and ancillary tests recommended for a correct diagnosis. The authors discuss the different drugs and its pathogenic mechanisms. The relevance of an early recognition and recommendations for a correct management are commented. Expert opinion: Prescribers need to remain vigilant for DIP, particularly in the elderly, patients taking multiple drugs and those with genetic risk factors involved in iPD. Cessation of the causing agent is the main treatment and there is no evidence of benefit for the use of anticholinergics or levodopa. If the medication cannot be withdrawn, it should be switched to agents with a lower risk of DIP.
引用
收藏
页码:487 / 496
页数:10
相关论文
共 127 条
[11]   FLUNARIZINE-INDUCED PARKINSONISM IN THE ELDERLY [J].
BENVENUTI, F ;
BARONI, A ;
BANDINELLI, S ;
FERRUCCI, L ;
CORRADETTI, R ;
PANTALEO, T .
JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 28 (07) :600-608
[12]   Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990 [J].
Bower, JH ;
Maraganore, DM ;
McDonnell, SK ;
Rocca, WA .
NEUROLOGY, 1999, 52 (06) :1214-1220
[13]   Thiethylperazine-induced parkinsonism:: in vivo demonstration of dopamine D2 receptors blockade [J].
Briani, C ;
Cagnin, A ;
Chierichetti, F ;
Tiberio, M ;
Battistin, L ;
Pizzolato, G .
EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 (10) :709-710
[14]   Substance Abuse and Movement Disorders [J].
Brust, John C. M. .
MOVEMENT DISORDERS, 2010, 25 (13) :2010-2020
[15]  
Carlsson A, 1965, Lakartidningen, V62, P1978
[16]  
CHOUZA C, 1986, LANCET, V1, P1303
[17]  
CLAPS A, 1995, REV MED CHILE, V123, P1033
[18]   A case of Parkinsonism due to lithium intoxication: Treatment with Pramipexole [J].
Dallocchio, C ;
Mazzarello, P .
JOURNAL OF CLINICAL NEUROSCIENCE, 2002, 9 (03) :310-311
[19]   EXTRAPYRAMIDAL SYMPTOMS ASSOCIATED WITH CALCIUM-CHANNEL BLOCKERS [J].
DANIEL, JR ;
MAURO, VF .
ANNALS OF PHARMACOTHERAPY, 1995, 29 (01) :73-75
[20]  
De Michele G, 1987, Acta Neurol (Napoli), V9, P230